Manufacturing Partnerships Ancora Biotech relies on external manufacturing and clinical development oversight for its three antibody programs, signaling a strong outsourcing need for GMP production, process development, and CMC support. This creates prime opportunities for CDMOs and CROs to offer end-to-end services, tech transfer, and scalable manufacturing solutions.

Licensing Opportunities With a small, private team and assets spanning clinical-stage and preclinical programs, Ancora Biotech appears open to licensing or co-development deals to advance IND filings and scale operations. Leverage executive networks and spin-off history to identify potential strategic partners in immuno-oncology, hepatology, and inflammatory diseases.

Immuno-Oncology Focus The lead asset TNB-486 is a CD19xCD3 bispecific antibody for B cell cancers, delivering a clear value proposition to oncology partners pursuing next-gen immuno-oncology therapies and cell-engager platforms.

Geriatrics and Virology Opportunities TNB-738 targets inflammatory and metabolic disorders in the elderly and TNB-Ten targets chronic hepatitis B, opening doors for partnerships with specialty pharma seeking assets in inflammatory disease, aging biology, and antiviral strategies.

Investor & Growth Enablement Ancora Biotech sits in the Palo Alto ecosystem with venture pedigree, offering potential for strategic investments and collaborations to fund late-stage development, manufacturing scale, and global trial execution.